Lisanti Capital Growth LLC Purchases New Stake in Axsome Therapeutics, Inc. $AXSM

by · The Markets Daily

Lisanti Capital Growth LLC acquired a new position in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM – Free Report) during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 20,825 shares of the company’s stock, valued at approximately $5,097,000.

Several other large investors have also recently bought and sold shares of AXSM. Kemnay Advisory Services Inc. acquired a new stake in Axsome Therapeutics in the fourth quarter valued at $31,000. Hollencrest Capital Management grew its stake in shares of Axsome Therapeutics by 400.0% during the 1st quarter. Hollencrest Capital Management now owns 200 shares of the company’s stock worth $34,000 after purchasing an additional 160 shares during the period. Ameriflex Group Inc. purchased a new position in shares of Axsome Therapeutics in the 4th quarter valued at about $37,000. Advisory Services Network LLC purchased a new position in shares of Axsome Therapeutics in the 3rd quarter valued at about $40,000. Finally, Farther Finance Advisors LLC lifted its stake in shares of Axsome Therapeutics by 602.6% in the fourth quarter. Farther Finance Advisors LLC now owns 274 shares of the company’s stock valued at $50,000 after purchasing an additional 235 shares during the period. Hedge funds and other institutional investors own 81.49% of the company’s stock.

Axsome Therapeutics Price Performance

Shares of NASDAQ AXSM opened at $218.20 on Thursday. The company has a current ratio of 1.43, a quick ratio of 1.34 and a debt-to-equity ratio of 1.52. The company’s 50-day moving average price is $233.99 and its 200 day moving average price is $205.84. Axsome Therapeutics, Inc. has a 52 week low of $111.54 and a 52 week high of $260.19. The stock has a market cap of $11.43 billion, a price-to-earnings ratio of -58.19 and a beta of 0.65.

Axsome Therapeutics (NASDAQ:AXSM – Get Free Report) last announced its earnings results on Monday, August 10th. The company reported ($0.99) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.89) by ($0.10). Axsome Therapeutics had a negative return on equity of 265.55% and a negative net margin of 24.68%.The business had revenue of $218.38 million for the quarter, compared to analyst estimates of $221.11 million. As a group, research analysts forecast that Axsome Therapeutics, Inc. will post -2.78 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on AXSM. UBS Group began coverage on shares of Axsome Therapeutics in a report on Tuesday, August 11th. They set a “market perform” rating on the stock. Royal Bank Of Canada dropped their target price on shares of Axsome Therapeutics from $304.00 to $297.00 and set an “outperform” rating for the company in a report on Tuesday, August 11th. Zacks Research downgraded shares of Axsome Therapeutics from a “hold” rating to a “strong sell” rating in a research report on Monday, July 20th. TD Cowen boosted their price target on Axsome Therapeutics from $275.00 to $300.00 and gave the stock a “buy” rating in a research note on Wednesday, June 17th. Finally, Wells Fargo & Company upped their price target on Axsome Therapeutics from $255.00 to $256.00 and gave the stock an “overweight” rating in a report on Tuesday, August 11th. Two analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating, two have given a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $267.60.

View Our Latest Analysis on Axsome Therapeutics

Insider Buying and Selling at Axsome Therapeutics

In related news, CFO Nick Pizzie sold 33,000 shares of Axsome Therapeutics stock in a transaction that occurred on Tuesday, June 9th. The stock was sold at an average price of $240.09, for a total transaction of $7,922,970.00. Following the completion of the transaction, the chief financial officer directly owned 42,867 shares in the company, valued at $10,291,938.03. The trade was a 43.50% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Mark Coleman sold 6,000 shares of the stock in a transaction on Monday, June 1st. The shares were sold at an average price of $230.30, for a total value of $1,381,800.00. Following the sale, the director owned 35,140 shares in the company, valued at approximately $8,092,742. This trade represents a 14.58% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 200,766 shares of company stock valued at $46,685,646. Company insiders own 20.60% of the company’s stock.

About Axsome Therapeutics

(Free Report)

Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for central nervous system (CNS) disorders. The company focuses on small-molecule drugs designed to address unmet medical needs in areas such as depression, migraine, narcolepsy and fibromyalgia. Axsome employs a precision medicine approach, leveraging pharmacologic innovation to target underlying mechanisms of disease and improve patient outcomes.

Axsome’s pipeline includes several late-stage and approved product candidates.

Featured Articles

Want to see what other hedge funds are holding AXSM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Axsome Therapeutics, Inc. (NASDAQ:AXSM – Free Report).